ISLCCC 2025
ISLCCC 2025 aims to feature emerging research results and insights from real world clinical experience to promote research collaborations and improve survivorship care throughout the world
Related Articles
Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced nonâsmall cell lung cancer.
Insurers reject up to one-third of new specialty oral blood cancer prescriptions
SAN DIEGO â Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented…
Azenosertib Shows Promising Efficacy in Platinum-Resistant Ovarian Cancer
Azenosertib monotherapy showed a 34.9% overall response rate in heavily pretreated, cyclin E1âpositive, platinum-resistant ovarian cancer, with a median duration of response of 5.5 months.
International Alzheimerâs prevention trial in young adults begins | WashU Medicine
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company
Codon 12 Mutations May Signal Benefit With RMC-6236 in PDAC
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Growing Evidence Indicates BMI Is Not Suitable for Many… : Oncology Times
An abstract is unavailable.
Pashtoon Kasi MD, MS – The Role of Circulating Tumor DNA (ctDNA) in Colorectal Cancer Management – ASCO GI 2025
Discover the role of ctDNA in managing colorectal cancer, from guiding treatment decisions to assessing the risk of overtreatment.
People with cancer want financial toxicity discussions âvery early and very oftenâ
Individuals with cancer expressed a preference for early and frequent provider-initiated discussions about financial toxicity, according to study findings.Researchers sent anonymous surveys to 5,774 people…
Emavusertib Holds Potential for Combination Therapies in AML/MDS
Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.